World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
Project Number5R24AI120942-09
Former Number3R24AI120942-05S1
Contact PI/Project LeaderWEAVER, SCOTT C
Awardee OrganizationUNIVERSITY OF TEXAS MED BR GALVESTON
Description
Abstract Text
ABSTRACT
As underscored by pandemic COVID-19, Zika, yellow fever and chikungunya viruses, new and emerging
viruses represent increasing threats to human health, yet their mechanisms of emergence remain poorly
understood, and effective interventions are not available for most. Research on their pathogenesis, ecology,
evolution, epidemiology, emergence mechanisms, diagnostics, vaccines and therapeutics remain critical public
health needs. The World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) comprises a
comprehensive, diverse collection of over 8,000 virus strains in 21 families, as well as antisera, antigens,
cDNA clones and other reagents to enable research worldwide. Approximately 400 new virus strains are added
annually, and 1000 viruses and reagents are shipped annually. The WRCEVA also maintains broad expertise
in both novel and traditional approaches to virus identification and characterization, and provides critical
support for emergency outbreak responses as exemplified by the rapid generation and distribution of critical
COVID and Zika reagents. This proposal seeks to continue these WRCEVA activities in support of NIH-funded
and other research on emerging viruses worldwide, through five Specific Aims:
1. Maintain a comprehensive set of emerging viruses, arboviruses and associated reagents to support
research and surveillance. The virus collection as well as antigens, antibodies, cDNA clones and other
reagents will be continually enhanced to capitalize on new emergence trends and technologies. Emphasis
during the first two years will be placed on the development of critical reagents for coronavirus research.
2. Discover, isolate and characterize newly acquired viruses to determine relationships and taxonomic
assignments, and to assess in vitro and in vivo host range. Clinical and field samples as well as viral
isolates will be received for identification and characterization, and added to the repository. Critical
phenotypes of newly discovered viruses and strains will be assessed by using in vitro and in vivo infections.
3. Perform sequencing and phylogenetic analyses of selected virus groups to determine evolutionary
histories and emergence mechanisms, patterns of spread/infection, and to rapidly determine the
sources of new outbreaks. Key virus strains will undergo genomic sequencing to generate databases that
can be exploited for the rapid determination of new outbreak sources, including potential bioterrorism.
4. Determine why yellow fever virus has not caused major urban epidemics in South America for many
decades, or ever in Asia. Our unique collection of virus strains and arbovirology expertise will be used to
examine hypotheses related to limitations on urban transmission by Aedes aegypti mosquitoes.
5. Train scientists in the identification and characterization of emerging viruses. To enhance research
and surveillance in the U.S. and worldwide, the most efficient way to limit spread of new outbreaks, training
in virus identification, characterization, and diagnostics will be provided to visiting scientists.
Public Health Relevance Statement
PROJECT NARRATIVE
Research on emerging viruses and arthropod-borne viruses requires diverse collections of virus strains as well
as antibodies, antigens and other reagents that cannot be made at many scientific institutions. The World
Reference Center for Emerging Viruses and Arboviruses (WRCEVA), established over 5 decades ago,
maintains a comprehensive, diverse collection of over 8,000 virus strains in 21 families, as well as related
reagents to enable emerging virus research worldwide.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2019-nCoVAdoptedAedesAfricanAntibodiesAntigenic DiversityAntigensArbovirusesAsiaBioterrorismCOVID-19COVID-19 pandemicChikungunya virusClinicalCollaborationsCollectionCommunitiesComplementary DNACoronavirusCryoelectron MicroscopyCulicidaeDatabasesDengueDevelopmentDiagnosticEbola virusEcologyElectron MicroscopyEmergency SituationEmergency responseEpidemicEpidemiologyEvolutionFamilyFlavivirusFoundationsFundingGenerationsGenetic VariationGenomicsGoalsGrowthHealthHumanImmune SeraIn VitroInfectionInstitutionInternationalInterventionLaboratoriesLocationMethodsMiddle East Respiratory Syndrome CoronavirusNational Institute of Allergy and Infectious DiseaseNew YorkPathogenesisPatternPhenotypePhylogenetic AnalysisPlayPrincipal InvestigatorPublic HealthQualifyingReagentRecording of previous eventsResearchResearch SupportRoleSamplingScientistSerologySourceSouth AmericaTaxonomyTechnologyTestingTherapeuticTrainingUnited States National Institutes of HealthUniversitiesVaccine DesignVaccinesViralViral GenomeVirusVirus DiseasesVisitYellow FeverYellow fever virusZIKAZoonosesanthropogenesisantibody diagnosticarthropod-bornebiodefensebioweaponcross immunitydeep sequencingeffective interventionemerging virushuman diseaseimprovedin vivonew outbreaknew pandemicnew technologynext generation sequencingnoveloutbreak responsepandemic diseaseprogramsrepositorytransmission processtrendvaccine developmentvector transmissionvirus identification
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
800771149
UEI
MSPWVMXXMN76
Project Start Date
01-February-2016
Project End Date
24-March-2025
Budget Start Date
01-April-2024
Budget End Date
24-March-2025
Project Funding Information for 2024
Total Funding
$987,497
Direct Costs
$624,998
Indirect Costs
$362,499
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$987,497
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R24AI120942-09
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R24AI120942-09
Patents
No Patents information available for 5R24AI120942-09
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R24AI120942-09
Clinical Studies
No Clinical Studies information available for 5R24AI120942-09
News and More
Related News Releases
No news release information available for 5R24AI120942-09
History
No Historical information available for 5R24AI120942-09
Similar Projects
No Similar Projects information available for 5R24AI120942-09